Exelixis [EXEL] vs Regeneron [REGN] Detailed Stock Comparison

Exelixis Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Exelixis Inc. wins in 12 metrics, Regeneron Pharmaceuticals, Inc. wins in 8 metrics, with 0 ties. Exelixis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Exelixis Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 16.51 18.00 Exelixis Inc.
Price-to-Book Ratio 5.57 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 9.30 9.51 Exelixis Inc.
PEG Ratio 11.69 -4.80 Exelixis Inc.
EV/EBITDA 12.00 16.72 Exelixis Inc.
Profit Margin (TTM) 33.73% 31.41% Exelixis Inc.
Operating Margin (TTM) 39.41% 23.13% Exelixis Inc.
EBITDA Margin (TTM) 39.41% 23.13% Exelixis Inc.
Return on Equity 35.53% 14.86% Exelixis Inc.
Return on Assets (TTM) 19.26% 5.91% Exelixis Inc.
Free Cash Flow (TTM) $844.34M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 17.29% 25.39% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) 5.14 5.50 Exelixis Inc.
Enterprise Value $11.06B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 4.77 4.95 Exelixis Inc.
Gross Profit Margin (TTM) 95.58% 84.95% Exelixis Inc.
Revenue per Share (TTM) $9 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $2.78 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.42 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 14.54% 2.55% Regeneron Pharmaceuticals, Inc.

Exelixis Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

EXEL
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Exelixis Inc.6.30%3.14%16.82%26.66%17.25%18.40%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Exelixis Inc.17.29%163.05%125.66%666.01%363.54%353.55%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Exelixis Inc. vs Regeneron Pharmaceuticals, Inc.

MetricEXELREGN
Market Information
Market Cap i$11.96B$80.98B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,444,310642,495
90 Day Avg. Volume i2,453,333617,765
Last Close$51.60$618.95
52 Week Range$33.76 - $52.96$476.49 - $821.11
% from 52W High-2.57%-24.62%
All-Time High$52.96 (May 28, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-2.57%-48.90%
Growth Metrics
Quarterly Revenue Growth0.06%0.03%
Quarterly Earnings Growth0.75%-0.08%
Financial Health
Profit Margin (TTM) i0.34%0.31%
Operating Margin (TTM) i0.39%0.23%
Return on Equity (TTM) i0.36%0.15%
Debt to Equity (MRQ) i9.309.51
Cash & Liquidity
Book Value per Share (MRQ)$8.23$304.65
Cash per Share (MRQ)$4.08$83.86
Operating Cash Flow (TTM) i$884.27M$4.98B
Levered Free Cash Flow (TTM) i$631.16M$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Exelixis Inc. vs Regeneron Pharmaceuticals, Inc.

MetricEXEL (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i16.5118.00
Forward P/E i11.6914.21
PEG Ratio i11.69-4.80
Price to Sales (TTM) i5.145.50
Price to Book (MRQ) i5.572.45
Market Capitalization
Market Capitalization i$11.96B$80.98B
Enterprise Value i$11.06B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i4.774.95
Enterprise to EBITDA i12.0016.72
Risk & Other Metrics
Beta i0.420.40
Book Value per Share (MRQ) i$8.23$304.65

Financial Statements Comparison: Exelixis Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricEXEL (2025)REGN (2025)
Revenue/Sales i2.32B14.34B
Cost of Goods Sold i83.70M2.10B
COGS % of Revenue i3.6%14.6%
Gross Profit i2.24B12.24B
Gross Margin i96.4%85.4%
Research & Development i825.00M5.85B
Operating Income (EBIT) i892.70M3.70B
Operating Margin i38.5%25.8%
EBITDA i942.27M5.00B
EBITDA Margin i40.6%34.8%
Pre-Tax Income i941.21M5.23B
Pre-Tax Income % of Revenue i40.6%36.5%
Income Tax i158.64M725.80M
Income Tax % of Revenue i6.8%5.1%
Net Income (Profit) i782.57M4.50B
Profit Margin i33.7%31.4%

Balance Sheet & Liquidity Metrics

MetricEXEL (2025)REGN (2025)
Cash & Equivalents i482.49M3.12B
Total Current Assets i1.44B18.02B
Total Current Assets % of Revenue i62.2%125.7%
Total Current Liabilities i405.64M4.37B
Total Current Liabilities % of Revenue i17.5%30.5%
Long-Term Debt i173.04M2.71B
Long-Term Debt % of Revenue i7.5%18.9%
Total Shareholders Equity i2.16B31.26B
Retained Earnings i-76.83M35.80B
Retained Earnings % of Revenue i-3.3%249.6%
Property, Plant & Equipment i418.60M1.54B

Cash Flow Statement Comparison

MetricEXEL (2025)REGN (2025)
Operating Cash Flow i1.02B6.30B
Operating Cash Flow % of Revenue i43.8%43.9%
Capital Expenditures i-8.43M0
Free Cash Flow i844.34M3.77B
FCF Margin i36.4%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase i-947.51M-3.97B

Short Interest & Institutional Ownership Analysis

MetricEXELREGN
Shares Short i27.26M2.55M
Short Ratio i9.574.46
Short % of Float i14.54%2.55%
Shares Outstanding i262.48M105.72M
Float Shares i211.44M98.55M
% Held by Insiders i1.96%1.98%
% Held by Institutions i105.66%91.08%
% Held by Public i-7.62%6.94%

Dividend Analysis & Yield Comparison: Exelixis Inc. vs Regeneron Pharmaceuticals, Inc.

MetricEXELREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026